We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Telix Radiopharmaceutical Production Facility Buildout Commences MELBOURNE, Australia and BRUSSELS, Belgium, March 22, 2022 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX...
EAU Updates Guidance for PSMA-PET Imaging MELBOURNE, Australia and LIÈGE, Belgium, March 21, 2022 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company...
Telix Expands Lutetium-177 Network with Eckert & Ziegler Clinical Supply Agreement MELBOURNE and LIEGE, Belgium, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX:...
Telix and Biokosmos Sign Distribution Agreement for Prostate Cancer Imaging in Greece and Cyprus MELBOURNE, Australia and ATHENS, Greece, Jan. 28, 2022 (GLOBE NEWSWIRE) -- Telix...
First Patient Dosed in ProstACT Program for Prostate Cancer Therapy MELBOURNE, Australia, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company...
Raphaël Ortiz Joins Telix as Chief Operating Officer, EMEA MELBOURNE, Australia and LIÈGE Belgium, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the...
First Patient Dosed in Study of Targeted Alpha Therapy Candidate for Bladder Cancer MELBOURNE, Australia and NANTES, France, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited...
FDA Approves Telix’s Prostate Cancer Imaging Product, Illuccix® MELBOURNE, Australia and INDIANAPOLIS, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the...
Telix and NUCLIBER Sign Distribution Agreement for Prostate Cancer Imaging in Spain MELBOURNE, Australia and MADRID, Spain, Dec. 07, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited...
Australian TGA Approves Illuccix® for Prostate Cancer Imaging MELBOURNE, Australia, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.58 | 2.81143965099 | 20.63 | 21.4 | 20.01 | 714446 | 20.53546457 | DE |
4 | 2.7 | 14.5867098865 | 18.51 | 21.4 | 17.77 | 1233715 | 19.88058579 | DE |
12 | 0.74 | 3.61504640938 | 20.47 | 21.4 | 17.03 | 1512483 | 19.11096462 | DE |
26 | 8.67 | 69.1387559809 | 12.54 | 21.4 | 12.01 | 1388116 | 17.93117814 | DE |
52 | 9.71 | 84.4347826087 | 11.5 | 21.4 | 8.2 | 1182920 | 14.98678011 | DE |
156 | 15.62 | 279.427549195 | 5.59 | 21.4 | 3.55 | 1132659 | 10.119505 | DE |
260 | 19.885 | 1500.75471698 | 1.325 | 21.4 | 0.755 | 965901 | 7.9601257 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions